Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2888 (LINC02888, also known as KCCAT333 or renal clear cell carcinoma-associated transcript 333) is a long intergenic non-coding RNA (lincRNA), defined as an RNA transcript longer than 200 nucleotides which does not overlap with protein-coding genes and is not translated into protein[1][3]. Its alternative name suggests an association with clear cell renal cell carcinoma, a common type of kidney cancer, but the specific function and mechanism of LINC02888 in this context remain uncharacterized in available sources. LincRNAs are known to regulate gene expression at various levels (epigenetic, transcriptional, post-transcriptional) and can act locally (cis) or at distant sites (trans)[1][3]. Some lincRNAs have been implicated in oncogenesis and as potential diagnostic or prognostic biomarkers in cancer, but it is unclear whether LINC02888 has a validated driver or therapeutic role[3]. The exact biological role, interacting molecules, and druggability of this lincRNA are not established in the current literature.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2888 (LINC02888).